Physician profile
Ali A Askari
NPI 1760554919
$5,505.75
in general payments reported to CMS, 2019-2025
36 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $442 · 2021: $810 · 2022: $1,073 · 2023: $969 · 2024: $896 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $913.43 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $735.71 | 2019-2022 | |
| Boston Scientific Corporation | $611.26 | 2019-2024 | Watchman Access System, Zoom Wireless Transmitter, Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $543.63 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $325.41 | 2022 | |
| Medtronic Vascular, INC. | $311.27 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $267.56 | 2019-2025 | Farxiga |
| Heartflow, INC. | $194.27 | 2023-2024 | Ffrct |
| Janssen Pharmaceuticals, INC | $193.02 | 2023-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $175.87 | 2022-2024 | Assure Wcd |
| Hitachi Healthcare Americas Corp. | $155.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $101.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.21 | 2019-2025 | Jardiance |
| Cmp Pharma, INC. | $82.58 | 2024-2025 | Atorvaliq, Tadliq, Carospir |
| Amarin Pharma, INC. | $75.31 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $75.00 | 2020-2022 | |
| Novo Nordisk INC | $66.49 | 2023-2024 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $63.38 | 2022-2025 | Verquvo |
| Pfizer INC. | $59.11 | 2023-2024 | |
| Edwards Lifesciences Corporation | $56.72 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Actelion Pharmaceuticals US, INC. | $46.18 | 2019-2024 | Opsumit |
| Atricure, INC. | $46.03 | 2024 | |
| Lucid Diagnostics INC. | $45.91 | 2022 | |
| Astellas Pharma US INC | $41.78 | 2019-2021 | |
| Genzyme Corporation | $32.47 | 2025 | |
| Cvrx, INC. | $26.91 | 2023 | Barostim Neo System |
| Chiesi USA, INC. | $26.52 | 2025 | Juxtapid |
| Philips North America LLC | $19.63 | 2022 | |
| Vifor Pharma, INC. | $19.32 | 2019 | |
| Amgen INC. | $19.09 | 2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $18.88 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $17.30 | 2023 | Arcalyst |
| Medtronic, INC. | $12.95 | 2021 | |
| Glaxosmithkline, LLC. | $12.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Askari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.